NCT03819881View on ClinicalTrials.gov

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions
BIOLOGICAL

STMC-103H

Live bacterial product

BIOLOGICAL

Placebo

Inactive placebo substance

Trial Locations (2)

92780

RECRUITING

Orange County Research Center, Tustin

95207

RECRUITING

Bensch Clinical Research LLC, Stockton

Sponsors

Collaborators (1)

Integrium
All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

Siolta Therapeutics, Inc.

INDUSTRY

NCT03819881 - A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy | Biotech Hunter | Biotech Hunter